American Society of Nephrology, Nov. 4 to 7

Kidney Week 2021



MONDAY, Nov. 15, 2021 (HealthDay News) — Treatment with sodium-glucose cotransporter 2 inhibitors could substantially reduce the risk for cardiovascular disease and end-stage kidney disease in patients with type 1 diabetes, especially those with albuminuria, according to a study presented at Kidney Week, the annual meeting of the American Society of Nephrology, held virtually from Nov. 4 to 7.

Read Full Text

ASN: Daprodustat Noninferior to ESAs for Treating Anemia in CKD

FRIDAY, Nov. 12, 2021 (HealthDay News) — For patients with chronic kidney disease who are and are not undergoing hemodialysis, the oral hypoxia-inducible factor prolyl hydroxylase inhibitor daprodustat is noninferior to injectable erythropoiesis-stimulating agent for the treatment of anemia, according to two studies published online Nov. 5 in the New England Journal of Medicine. The research was published to coincide with Kidney Week, the annual meeting of the American Society of Nephrology, held virtually from Nov. 4 to 7.

Read Full Text

ASN: Chlorthalidone Aids BP Control in Patients With CKD and HTN

FRIDAY, Nov. 12, 2021 (HealthDay News) — Compared with placebo, chlorthalidone therapy improves blood pressure control at 12 weeks among patients with advanced chronic kidney disease and poorly controlled hypertension, according to a study published online Nov. 5 in the New England Journal of Medicine. The research was published to coincide with Kidney Week, the annual meeting of the American Society of Nephrology, held virtually from Nov. 4 to 7.

Read Full Text

1 | 2 | 3
Page 3 of 3
« Prev